within Pharmacolibrary.Drugs.ATC.V;

model V03AE03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 2e-05,
    Cl             = 1.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,
    adminCount     = 1,
    Vd             = 0.000107,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Lanthanum carbonate is a non-calcium, non-aluminum phosphate binder used to treat hyperphosphatemia in patients with end-stage renal disease. It reduces phosphate absorption from the gastrointestinal tract by binding dietary phosphate, forming insoluble lanthanum-phosphate complexes that are excreted in the feces. Lanthanum carbonate is approved and widely used for this purpose.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic profile in adult patients with chronic kidney disease; the drug is minimally absorbed from the gastrointestinal tract.</p><h4>References</h4><ol><li><p>Freemont, AJ (2006). Lanthanum carbonate. <i>Drugs of today (Barcelona, Spain : 1998)</i> 42(12) 759–770. DOI:<a href=&quot;https://doi.org/10.1358/dot.2006.42.12.1025698&quot;>10.1358/dot.2006.42.12.1025698</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17285149/&quot;>https://pubmed.ncbi.nlm.nih.gov/17285149</a></p></li><li><p>Pierce, D, et al., &amp; Smyth, M (2011). The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. <i>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</i> 26(5) 1615–1621. DOI:<a href=&quot;https://doi.org/10.1093/ndt/gfq598&quot;>10.1093/ndt/gfq598</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20921291/&quot;>https://pubmed.ncbi.nlm.nih.gov/20921291</a></p></li><li><p>Damment, SJ, &amp; Pennick, M (2008). Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. <i>Clinical pharmacokinetics</i> 47(9) 553–563. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200847090-00001&quot;>10.2165/00003088-200847090-00001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18698878/&quot;>https://pubmed.ncbi.nlm.nih.gov/18698878</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V03AE03;
